Short Courses

Our short courses are designed to be instructional, interactive, and provide in-depth information on a specific topic. They allow for one-on-one interaction between the participants and instructors to facilitate the explanation of the more technical aspects that would otherwise not be covered during our main presentations.

Short Courses Will Be Offered In Person Only

Sunday, May 11, 2025  2:00 - 5:00 pm

SC1: In silico and Machine Learning Tools for Antibody Design and Developability Predictions

Detailed Agenda
Given the exciting pace in the evolution of machine learning tools towards antibody design and developability predictions, we plan to present an overview in this field specifically geared towards antibody design and developability predictions. There will be a live demo of a few ML tools.
Mehdi Boroumand, PhD, Associate Principal Data Scientist, Machine Learning, AstraZeneca
Henriette Capel, PhD Student, University of Oxford
Vinodh B. Kurella, PhD, Biotherapeutic Computational Modeler, Takeda Pharmaceuticals, Inc.
Robert Vernon, PhD, Associate Director, Amgen

Topics to be covered include: 

  • Overview of sequence, structure-guided, ML (machine learning) tools for developability and designs 
  • Overview and demo of various ML tools from Oxford Protein Informatics Group (OPIG)
  • Antibody numbering tools (ANARCII - Greenshields-Watson et al. 2025)
  • Antibody (and nanobody) structure prediction (ABodyBuilder2 - Abanades et al. 2023)   
  • Therapeutic antibody profiling and developability evaluation (TAP - Raybould et al. 2019, TAP2 - Raybould et al. 2024)  
  • Antibody humanisation (Humatch - Chinery et al. 2024) 
  • Antibody sequence optimization with inverse folding (AntiFold - Høie et al. 2025)
  • In silico developability assessment - case studies

INSTRUCTOR BIOGRAPHIES:

Mehdi Boroumand, PhD, Associate Principal Data Scientist, Machine Learning, AstraZeneca

Mehdi Boroumand is an Associate Principal Data Scientist at AstraZeneca, working in the Machine Learning and AI group within the Biopharmaceutical Development department. He is the Machine Learning team lead for the in-silico prediction of developability attributes of antibodies, as part of AstraZeneca’s MLAB (Machine Learning Driven Antibodies and Biologics) project. He holds a PhD in Electrical Engineering from the State University of New York at Binghamton.

Henriette Capel, PhD Student, University of Oxford

I'm a PhD student in the Oxford Protein Informatics Group, supervised by Professor Charlotte Deane. My research is focused on machine learning tools for the prediction of antibody developability.

Vinodh B. Kurella, PhD, Biotherapeutic Computational Modeler, Takeda Pharmaceuticals, Inc.

Vinodh Kurella is a Senior Scientist (Biologics computational modeler) in Biotherapeutic Engineering Group (BE) within Global Biologics at Takeda (Cambridge, USA). Experienced in structure-based antibody/protein design and optimization. Previously had range experiences at various biotech companies in different modalities such as gene therapy, biologics, and CAR T designs. Post-doctoral training at Harvard Medical School/Dana Farber in Dr. Wayne Marasco laboratory in antibody engineering and graduate training from Louisiana State University (LSU-HSC) in the field of protein X-ray crystallography in David Worthylake laboratory.

Robert Vernon, PhD, Associate Director, Amgen

Robert Vernon is an Associate Director at Amgen, working in the Digital Biologics Discovery group within Amgen's Center for Research Innovation through Digital Innovation (CRADI). He manages the implementation and development of ML platforms for generative protein design within pre-clinical development. PhD training at the University of Washington under Dr. David Baker (protein structure prediction and design), Post-doctoral training at SickKids hospital in Toronto under Dr. Julie Forman-Kay (protein condensate prediction and design).

 

SC2: Safety & Efficacy of Bispecifics and ADCs

Detailed Agenda
Bispecific immunotherapies and ADCs are the two most rapidly advancing cancer therapeutics in the war against cancer. However, efficacy and safety challenges limit their therapeutic effectiveness in resistant and refractory cancers. The short course will discuss the translational aspects of bispecifics and ADCs; efficacy and safety challenges originating from poorly constructed ADCs; five rights of the targets, effector arms, and constructs for attaining the best therapeutic index for bispecifics and ADCs as well as strategies to minimize toxicities of bispecific and ADCs.
Rakesh Dixit, PhD, DABT, CEO & President, Bionavigen Oncology, LLC and CSO, TMAB Therapeutics, Regio Biosciences

The short course will discuss:

  • ​Bispecific and ADC landscape assessment and unmet medical needs
  • Efficacy and safety challenges originating from poorly constructed ADCs
  • Five rights of the targets, effector arms, and constructs for attaining the best therapeutic index for bispecifics and ADCs
  • Minimizing toxicities of bispecifics and ADCs
  • Translational aspects of bispecific and ADC development


INSTRUCTOR BIOGRAPHIES:

Rakesh Dixit, PhD, DABT, CEO & President, Bionavigen Oncology, LLC and CSO, TMAB Therapeutics, Regio Biosciences

Rakesh Dixit is an accomplished executive, inventor, and scientist with over 35 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, and Medimmune - AstraZeneca. Currently, he is President and CSO of Regio Biosciences and Bionavigen, LLC. He is a Board Member of Regio Biosciences and a key member of multiple scientific advisory boards. Rakesh is also a chief adviser and consultant for more than 20 companies worldwide. His biopharmaceutical peers selected Rakesh as one of the 100 Most Inspiring People in the Pharmaceutical Industry by PharmaVOICE in 2015. Rakesh received the Most Prestigious Award of Long-Standing Contribution to ADCs by World ADC (Hanson-Wade), 2020. From 2006 to 2019, Rakesh was a Global Vice President of the Biologics R&D at Medimmune - AstraZeneca. Rakesh has unique expertise in developing biologics (e.g., monoclonal antibodies, bispecific biologics, antibody-drug conjugates, fusion proteins, peptides, gene and cell therapies, etc.) and small-molecule biopharmaceuticals. His areas of expertise include discovery, early and late preclinical development, safety assessment, DMPK, and translational sciences. Dr. Dixit conducted extensive graduate and post-graduate training in Pharmacology/Toxicology–Biochemistry with both Indian and USA institutions (e.g., Case Western Reserve University, Medical College of Ohio, University of Nebraska) and is a Diplomate and Board Certified in Toxicology from the American Board of Toxicology, Inc. since 1992.

 

SC3: Challenges and Opportunities in Solid Tumor and Autoimmune Disease Therapeutic Innovations

Detailed Agenda
This course offers advanced insights into developing next-generation immunotherapies for solid tumors and autoimmune diseases, focusing on identifying new biological targets and therapeutic methods. It includes detailed analyses of the solid tumor microenvironment and the autoimmune diseases space, addressing challenges and showcasing successful therapeutic strategies across T cell engagers, blocking bispecific antibodies, ADCs, CAR-Ts, radioligand therapy and targeted protein degraders. Additionally, the course will explore the use of machine learning and generative AI to identify novel therapeutic targets and accelerate the development of treatments.
Tony R. Arulanandam, DVM, PhD, CEO and Founder, Synaptimmune Therapeutics
  • Identify and develop next-generation immunotherapies for solid tumors and autoimmune diseases
  • Analyze the solid tumor microenvironment, discussing successful therapies such as T cell engagers, blocking bispecific antibodies, ADCs, CAR-Ts, Radio ligand therapy and Targeted Protein degraders
  • Examines autoimmune disease biology and therapeutic development, integrating approaches like immune target blockade and autoantigen tolerizing.
  • Highlights the application of machine learning and generative AI in discovering novel therapeutic targets and expediting therapeutic development.
  • Addresses the challenges and provides case examples of cutting-edge therapeutic approaches in both cancer and autoimmune diseases

INSTRUCTOR BIOGRAPHIES:

Tony R. Arulanandam, DVM, PhD, CEO and Founder, Synaptimmune Therapeutics

Tony Arulanandam, DVM, PhD, is CEO and Founder Synaptimmune Therapeutics, a Yale Ventures spinout newco developing next generation of IDR-CAR-T cells with increased potency and antigen sensitivity against blood cancers, solid tumors and autoimmunity. Senior Vice President and Head of Preclinical Research and Development at Cytovia Therapeutics focused in developing NK Cell engager bispecific antibodies and iPSC derived CAR-NK therapies for cancer. He is also the Co-Founder of NextPoint therapeutics, an MPM capital-funded IO checkpoint immunotherapy company. He is an immunologist with 20+ years of research and development experience developing multiple immunotherapies for autoimmune/inflammatory diseases and cancer (5 BLAs and multiple INDs). He is also currently a mentor for postdocs at the Dana-Farber Cancer Institute through the Post-Graduate Association.

Tuesday, May 13, 2025  6:30 - 9:00 pm

SC4: Best Practices for Targeting GCPRs, Ion Channels, and Transporters with Monoclonal Antibodies

Detailed Agenda
Complex membrane proteins are important therapeutic targets and together represent the majority of protein classes addressed by therapeutic drugs. Significant opportunities exist for targeting complex membrane proteins with antibodies, but it has been challenging to discover therapeutic antibodies against them. This course will examine emerging technologies and strategies for enabling the isolation of specific and functional antibodies against GPCRs, ion channels, and transporters, and highlight progress via case studies.
Ross Chambers, PhD, Vice President, Antibody Discovery, Integral Molecular, Inc.

INSTRUCTOR BIOGRAPHIES:

Ross Chambers, PhD, Vice President, Antibody Discovery, Integral Molecular, Inc.

Ross Chambers is the Vice President of Antibody Discovery at Integral Molecular. He pioneered the use of DNA immunization for antibody production and developed Integral Molecular’s MPS system for isolating antibodies. Dr. Chambers earned his PhD from the University of Otago, New Zealand, and did post-doctoral studies at UC Davis and Berkeley. Before joining Integral Molecular, he was the Director of R&D at SDIX and directed the discovery of thousands of commercial antibodies.

 

SC5: Targeting the Target: Aligning Target and Biologic Format Biology to Achieve Desired Outcomes

Detailed Agenda
Receptor – ligand interactions have co-evolved to maintain specificity of downstream signaling. However, biologics are not natural ligands and, therefore, different biologics to the same target (receptor or ligand) can have distinct outcomes. Recent advances in various high-throughput analytical technologies, biologic-based therapeutic formats, and our understanding of disease heterogeneity are & will challenge us to “re-evaluate” our discovery and development paradigm(s). In this course we will explore, with examples, potential avenues on how to apply these new technologies/understanding to select “better” lead candidates to achieve “better” desired outcomes.
Tariq Ghayur, PhD, Tariq Ghayur Consulting, LLC; Entrepreneur in Residence, FairJourney Biologics

Topics to be covered

  • Introduction to the “components of success paradigm”
  • Underlying concepts and examples of one target, multiple functions/outcomes
  • How emerging technologies are and could impact
  • o    Understanding target biology, lead selection and discovery/development paradigm
  • o    Target space for bispecifics, ADCs and other therapeutic formats/concepts
  • Case studies: (i) evaluating functional impact of different mAbs to the same target (target/mAb biology): (ii) designing biologic molecules to develop functional assays to assess novel/emerging target biology and potentially develop novel therapeutics

INSTRUCTOR BIOGRAPHIES:

Tariq Ghayur, PhD, Tariq Ghayur Consulting, LLC; Entrepreneur in Residence, FairJourney Biologics

Dr. Ghayur retired from AbbVie (July 2021) and works as an independent consultant. He has 30+ years’ experience leading multi-disciplinary and cross-therapeutic area Biologics discovery programs and developing novel Biologics platforms. Several biologics programs resulted in clinical development candidates. Dr. Ghayur led the team that pioneered the discovery and development of the Dual – variable – Domain -Ig (DVD-Ig) and other multi-specific platforms. Dr. Ghayur also led the team that defined the uptake, intracellular trafficking, and lysosomal degradation of anti-TNF mAbs/DVD-Ig, resulting in the concept of anti-TNF-ADC (next-Gen anti-TNF). In addition, Dr. Ghayur proposed and helped implement several corporate-wide (Abbott & AbbVie) initiatives to foster cross-functional/cross-TA collaborations to bring forward innovative concepts/programs.

 

SC6: Developability of Bispecific Antibodies

Detailed Agenda
Bispecific antibodies are a rapidly growing and clinically validated class of antibodies with marketed drugs and multiple candidates in clinical trials. Targeting multiple antigens in a synergistic manner can confer enhanced therapeutic benefit and potentially uncover novel biological mechanisms. However, multiple formats and a tedious candidate selection process to select functional and developable bispecific antibodies makes such programs cumbersome. This short course highlights the rapid growth in the field, therapeutic applications, and focuses on challenges with discovery and development of bispecific antibodies. We will use an approved bispecific antibody as a case study to understand the varied aspects of discovery and development of bispecific antibody programs.
Nimish Gera, PhD, Independent Consultant

Topics to be covered 

  • Introduction to bispecifics and bispecific formats 
  • Therapeutic applications of bispecific antibodies 
  • Developability of bispecifics 
  • Case study: discovery and development of an FDA-approved bispecific antibody​

INSTRUCTOR BIOGRAPHIES:

Nimish Gera, PhD, Independent Consultant

Nimish Gera is the Vice President of Biologics at Mythic Therapeutics leading multiple projects to engineer and develop novel antibody and antibody-based drugs in oncology and immuno-oncology. Prior to Mythic, Nimish has over fifteen years of experience in antibody and protein engineering with five years leading bispecific antibody programs in several disease areas such as rare diseases, oncology, and immunology at Alexion Pharmaceuticals and Oncobiologics. Nimish received his PhD degree in Chemical and Biomolecular Engineering from North Carolina State University and a B.Tech degree in Chemical Engineering from Indian Institute of Technology, Guwahati.





Register

View By:


Premier Sponsors

FairJourneyBiologics GenScript-CRO Integral-Molecular_NEW   Nona_Biosciences_NEW